LFS302: Real World Evidence Platforms to Enable Therapeutic Innovation

Historically, there has been an information asymmetry in pharmaceutical R&D where the biopharmaceutical companies had the deepest understanding and knowledge about their products and how they helped and interacted with patients. Now, there's new, real-world data that exists from regulators, health plans, government authorities, and patients, which is helping pharma companies to understand how their therapies and their innovations drive value and impact in patient populations. There are imperatives to leverage that data, create new partnerships in their ecosystem, and get access to that data in an ethical way to derive insights to both fuel innovation and drive discovery. In this session, you learn best practices from Deloitte and Celgene about strategy, operating models, and execution frameworks when implementing a real-world, evidence data platform.